Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye-Tracking tech could spot macular degeneration faster

NCT ID NCT06518512

Diagnosis Sponsor: Tan Tock Seng Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called AVIGA that tracks eye movements to detect vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the device's results with standard eye exams to see if it can reliably spot disease activity. The goal is to develop a quick, automated way to monitor AMD over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system
What this could lead to
If successful, this could lead to a simple, automated eye-tracking test to detect and monitor wet age-related macular degeneration without the need for complex equipment.
What could go wrong
This is an early-stage study with 128 participants, so results may not apply to everyone. The device is not yet proven to replace standard tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients of both genders aged 55 years and above diagnosed with wet AMD. Participants recruited must be cognitively coherent.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects in the age group = 55 years and above. * Both genders * Subjects with Wet-AMD * Ability to comply with the study protocol, in the investigator\'s judgment * Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments are done. Exclusion Criteria: * Uncontrolled blood pressure, defined as systolic blood pressure \>180 millimeters of mercury (mmHg) and/or diastolic blood pressure \>100 mmHg while a patient is at rest. * Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye * Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study * History of idiopathic or autoimmune-associated uveitis in either eye * Active ocular inflammation or suspected or active ocular or periocular infection in either eye * Other protocol-specified exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration Wet age related macular degeneration

Contacts and locations

Locations

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.